<DOC>
	<DOCNO>NCT01273597</DOCNO>
	<brief_summary>This observational study evaluate clinical benefit Zemplar ( paricalcitol injection ) daily routine practice end-stage renal disease patient severe over-reactivity parathyroid gland . Participants follow 6 month . Data collect participant initiated Zemplar therapy accord standard care . The time achieve maintenance dose Zemplar ( paricalcitol injection ) , proportion participant achieve target parathyroid hormone level , prevalence elevate serum calcium phosphate level evaluate .</brief_summary>
	<brief_title>Observational Study Evaluate Time Achieving Maintenance Dose Zemplar® ( Paricalcitol Injection ) Treatment Patients Suffering From End-stage Renal Disease Severe Over-reactivity Parathyroid Glands</brief_title>
	<detailed_description>Prospective data collection start initial dose Zemplar ( paricalcitol injection ) end 6 month later . If available , retrospective data vitamin D treatment well incidence hypercalcaemia hyperphosphataemia 6 month lead paricalcitol treatment also collect . Eight visit plan documentation prospective data . In accordance non-interventional character study , diagnostic monitoring procedure apply part routine medical care secondary hyperparathyroidism .</detailed_description>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<criteria>Based current Hungarian Summary Product Characteristics Zemplar ( paricalcitol injection ) , patient entitle treatment paricalcitol injection : 1 . ≥ 18 year age , 2 . Willing sign patient information inform consent form , 3 . Chronic kidney disease ( CKD ) stage 5 patient receive haemodialysis diagnosis secondary hyperparathyroidism ( SHPT ) , whose intact parathyroid hormone ( iPTH ) level : 500800 pg/mL least two abruption conventional vitamin D therapy due elevate serum calcium level ( i.e . &gt; 2.4 mmol/L ) medical history , high 800 pg/mL parathyroidectomy contraindicate . 4 . The patient plan receive paricalcitol treatment independently his/her participation study . Patients enrol study follow exclusion criterion apply : 1 . The patient already treat Zemplar ( paricalcitol injection ) , 2 . Any contraindication exist state current Hungarian Summary Product Characteristics Zemplar ( paricalcitol injection ) , 3 . Patients decline participate study decline sign patient information/informed consent form .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Parathyroid hormone , Kidney failure , chronic , Hyperparathyroidism , secondary</keyword>
</DOC>